{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:26:48Z","timestamp":1790526408712,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/s1470-2045(12)70200-0","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T21:17:02Z","timestamp":1338931022000},"page":"716-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":251,"title":["Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial"],"prefix":"10.1016","volume":"13","author":[{"given":"Michael","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Wagner-Bartak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate J","family":"Newberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bejarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hartig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Zeldis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(12)70200-0_bib1","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fern\u00e0ndez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"10.1016\/S1470-2045(12)70200-0_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib4","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib6","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/cncr.23880","article-title":"Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(12)70200-0_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib9","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1200\/JCO.2011.34.7252","article-title":"Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy","volume":"29","author":"Rubenstein","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1749-6632.2011.05974.x","article-title":"A review of the history, properties, and use of the immunomodulatory compound lenalidomide","volume":"1222","author":"Zeldis","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/S1470-2045(12)70200-0_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib12","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/jco.2007.25.18_suppl.3023","article-title":"Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab","volume":"25","author":"Bartlett","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib13","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(12)70200-0_bib15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/S1470-2045(12)70200-0_bib17","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S1470-2045(12)70200-0_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib19","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(12)70200-0_bib21","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib23","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib26","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(12)70200-0_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204512702000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204512702000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:04:35Z","timestamp":1761458675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204512702000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1470204512702000"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(12)70200-0","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(12)70200-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(12)70223-1","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}